JRCT ID: jRCT2011210069
Registered date:05/02/2022
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Systemic Lupus Erythematosus |
Date of first enrollment | 15/02/2022 |
Target sample size | 20 |
Countries of recruitment | Argentina,Japan,Australia,Japan,Brazil,Japan,Chile,Japan,Colombia,Japan,France,Japan,Germany,Japan,Ireland,Japan,Mexico,Japan,Poland,Japan,Romania,Japan,Spain,Japan,Taiwan,Japan,USA,Japan,United Kingdom,Japan |
Study type | Interventional |
Intervention(s) | Arm A: Afimetoran 30mg QD Arm B: Afimetoran 10mg QD Arm C: Afimetoran 2.5mg QD Arm D: Placebo QD |
Outcome(s)
Primary Outcome | Proportion of participants that achieve an SLE (Systemic Lupus Erythematosus) Responder Index (4) (SRI(4)) response at Week 48 |
---|---|
Secondary Outcome | 1. Proportion of participants that achieve an SRI(4) response with corticosteroids (CS) reduction and maintenance to <- 7.5 mg per day at Week 48 2. Proportion of participants that achieve a British Isles Lupus Assessment Group (BILAG)-based Combine Lupus Assessment (BICLA) at Week 24 and Week 48 3. Proportion of participants who achieve an SRI(4) response without CS reduction and maintenance to <- 7.5 mg per day at Week 24 4. Proportion of participants who achieve a Lupus Low Disease Activity State (LLDAS) response at Week 24 and Week 48 5. Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index; Activity (CLASI-A) score >- 10 at baseline who achieve a decrease of >- 50% from baseline CLASI-A score (CLASI-50) response at Week 24 and Week 48 6. Proportion of participants with 6 or more swollen joints and 6 or more tender joints at baseline who achieve a >- 50% reduction from baseline in both swollen and tender joints at Week 24 and Week 48 7. Mean change from baseline in swollen joint count using the 28-joint count at Week 24 and Week 48 in participants with >- 2 swollen joints at baseline 8. Mean change from baseline in tender joint count at Week 24 and Week 48 using the 28- joint count in participants with >- 2 tender joints at baseline 9. Change from baseline in PGA score of disease activity at Week 24 and Week 48 PGA = Physician Global Assessment of disease activity 10. Proportion of participants who achieve CS reduction or maintenance to <- 7.5 mg per day at Week 48 11. Change in patient reported disease activity from baseline to Week 24 and Week 48 according to the (36-item Short Form Health Questionnaire) SF-36 12. Number of participants that experience Serious Adverse Events (SAEs) 13. Proportion of participants that experience SAEs 14. Number of participants that experience Adverse Events (AEs) |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | <= 70age old |
Gender | Both |
Include criteria | - Qualify as having Systemic Lupus Erythematosus (SLE), according to the SLE International Collaborating Clinics (SLICC) Classification Criteria >- 12 weeks before the screening visit - Test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody>/= 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or anti-Smith antibody. - Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score >- 6 points and clinical Hybrid SLEDAI score >- 4 points with joint involvement and/or rash |
Exclude criteria | - Active severe lupus nephritis (LN) as assessed by the investigator - Neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI - Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is not SLE - Antiphospholipid Syndrome |
Related Information
Primary Sponsor | Ranganathan Usha |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04895696 |
Contact
Public contact | |
Name | Usha Ranganathan |
Address | 1-2-1 Otemachi, Chiyoda-ku, Tokyo Tokyo Japan 100-0004 |
Telephone | +81-120-093-507 |
MG-JP-RCO-JRCT@bms.com | |
Affiliation | Bristol-Myers Squibb |
Scientific contact | |
Name | Usha Ranganathan |
Address | 1-2-1 Otemachi, Chiyoda-ku, Tokyo Tokyo Japan 100-0004 |
Telephone | +81-120-093-507 |
mg-jp-clinical_trial@bms.com | |
Affiliation | Bristol-Myers Squibb |